Podoplanin Inhibitor / Contact Normalization Therapy

About Sentrimed

Sentrimed is an emerging, private biotech company founded in 2015, advancing a novel oncology platform centered on 'contact normalization'—a cellular communication process that enables normal cells to inhibit and destroy tumor cells. Led by a team with deep oncology experience, including founder and CSO Dr. Gary Goldberg, the company is developing a pipeline of oral, tumor-agnostic therapies and has compounds in human trials. While still pre-revenue, Sentrimed's approach targets a broad range of cancers and is supported by NIH grants, positioning it in a competitive but high-potential segment of the oncology market.

Therapeutic Areas